Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy

Alzheimer's and Dementia

Volumn 3, Issue 4, 2007, Pages 283-291

  Massoud, Fadi ^a   Belleville, Sylvie ^b,c   Bergman, Howard ^d,e   Kirk, John ^d   Chertkow, Howard ^b,d,e,f   Nasreddine, Ziad ^g   Joanette, Yves ^b,c   Freedman, Morris ^h  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE DE RECHERCHE   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g HÔPITAL CHARLES LEMOYNE   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

CIND; Cognitive impairment; Cognitive intervention; Exercise; MCI; Psychosocial intervention

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; APOLIPOPROTEIN E4; BENDROFLUMETHIAZIDE; BETA SECRETASE INHIBITOR; CAPTOPRIL; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYANOCOBALAMIN; DONEPEZIL; ENALAPRIL; ESTROGEN; FOLIC ACID; GALANTAMINE; GAMMA SECRETASE INHIBITOR; GINKGO BILOBA EXTRACT; HOMOCYSTEINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INDAPAMIDE; NITRENDIPINE; PERINDOPRIL; PHOSPHATIDYLSERINE; PLACEBO; PYRIDOXINE; RALOXIFENE; RIVASTIGMINE; ROFECOXIB; UNINDEXED DRUG;

CANADA; CASE CONTROL STUDY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; DEMENTIA; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG DOSE COMPARISON; EVIDENCE BASED MEDICINE; EXERCISE; FRUIT JUICE; GENOTYPE; HUMAN; HYPERTENSION; LIFESTYLE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MENTAL TASK; METHODOLOGY; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; NUTRITIONAL HEALTH; PATIENT CARE; PATIENT MONITORING; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RED WINE; REVIEW; SMOKING CESSATION; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 35048870714     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.07.002     Document Type: Review

References (46)

1. Chertkow H. Mild cognitive Impairment and very early stage Alzheimer's disease. In: Gauthier S (Ed). Clinical diagnosis and management of Alzheimer's disease. third edition (2006), Informa UK, London 205-221
2. Chertkow H. Emerging pharmacological therapies for mild cognitive impairment. In: Hultsch (Ed). Mild cognitive impairment: international perspectives (2006), Taylor & Francis, New York 217-243 IHTaD
3. Kramer A.F., Bherer L., Colcombe S.J., Dong W., and Greenough W.T. Environmental influences on cognitive and brain plasticity during aging. J Gerontol A Biol Sci Med Sci 59 (2004) M940-M957
4. Lindstrom H.A., Fritsch T., Petot G., Smyth K.A., Chen C.H., Debanne S.M., et al. The relationships between television viewing in midlife and the development of Alzheimer's disease in a case-control study. Brain Cogn 58 (2005) 157-165
5. Wilson R.S., Barnes L.L., Mendes de Leon C.F., Aggarwal N.T., Schneider J.S., Bach J., et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287 (2002) 742-748
6. Verhaeghen P., Marcoen A., and Goossens L. Improving memory performance in the aged through mnemonic training: a meta-analytic study. Psychol Aging 7 (1992) 242-251
7. Ball K., Berch D.B., Helmers K.F., Jobe J.B., Leveck M.D., Marsike M., et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288 (2002) 2271-2281
8. Olazarán J., Muniz R., Resiberg B., Pena-Casanova J., del Ser T., Cruz-Jentoft A.J., et al. Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology 63 (2004) 2348-2353
9. Rapp S., Brenes G., and Marsh A.P. Memory enhancement training for older adults with mild cognitive impairment: a preliminary study. Aging Ment Health 6 (2002) 5-11
10. Gunther V.K., Schafer P., Holzner B.J., and Kemmler G.W. Long-term improvements in cognitive performance through computer-assisted cognitive training: a pilot study in a residential home for older people. Aging Ment Health 7 (2003) 200-206
11. Belleville S., Gilbert B., Fontaine F., Gagnon L., Menard E., and Gauthier S. Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention program. Dement Geriatr Cogn Disord 22 (2006) 486-499
12. Lytle M.E., Vander Bilt J., Pandav R.S., Dodge H.H., and Ganguli M. Exercise level and cognitive decline: the MoVIES project. Alzheimer Dis Assoc Disord 18 (2004) 57-64
13. Laurin D., Verreault R., Lindsay J., MacPherson K., and Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 58 (2001) 498-504
14. Wilson R.S., Beckett L.A., Barnes L.L., Schneider J.A., Bach J., Evans D.A., et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging 17 (2002) 179-193
15. Colcombe S., and Kramer A.F. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychol Sci 14 (2003) 125-130
16. Heyn P., Abreu B.C., and Ottenbacher K.J. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 85 (2004) 1694-1704
17. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennett D.A., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51 (2002) 145-155
18. Terry Jr. A.V., and Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306 (2003) 821-827
19. Salloway S., Ferris S., Kluger A., Goldman R., Griesing T., Kumar D., et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63 (2004) 651-657
20. Petersen R.C., Thomas R.G., Grundman M., Bennet D., Doody R., Ferris S., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352 (2005) 2379-2388
21. Blacker D. Mild cognitive impairment: no benefit from vitamin E, little from donepezil. N Engl J Med 352 (2005) 2439-2441
22. Ferris S., Feldman H., Sfikas N., Mancione L., and Lane R. Time to clinical diagnosis of dementia in MCI subjects receiving rivastigmine: a randomized, double-blind, placebo-controlled study. Int Psychogeriatr 17 (2005) 242 (abstract)
23. Feldman H.H., Ferris S., Winblad B., Sfikas N., Mancione L., He Y., et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6 (2007) 501-512
24. Scheltens P., Fox N.C., Barkhof F., and Gold M. Effect of galantamine treatment on brain atrophy as assessed by MRI in patients with mild cognitive impairment. Neurobiol Aging 25 Suppl 2 (2004) S270-S271
25. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 (2003) 128-131
26. Thal L.J., Ferris S.H., Kirby L., Block G.A., Lines C.R., Yuen E., et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30 (2005) 1204-1215
27. Massoud F., Yaffe K., and Sano M. Estrogen. In: Qizillbash N. (Ed). Evidence-based dementia practice (2002), Blackwell Science, Oxford, UK 523-526
28. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study-a randomized controlled trial. JAMA 289 (2003) 2651-2662
29. Yaffe K., Krueger K., Cummings S.R., Blackwell T., Henderson V.W., Sarkar S., et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 162 (2005) 683-690
30. van Dongen M., van Rossum E., Kessels A., Sielhorst H., and Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 56 (2003) 367-376
31. Birks J., Grimley E.V., and Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (2002) CD003120
32. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., and Wilson R.S. Vitamin E and cognitive decline in older persons. Arch Neurol 59 (2002) 1125-1132
33. Engelhart M.J., Gerlings M.I., Ruitenberg A., van Swieten J.C., Hofman A., Witteman J.C., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287 (2002) 3223-3229
34. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. New Engl J Med 336 (1997) 1216-1222
35. Miller III E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005) 37-46
36. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., and Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53 (1999) 1937-1942
37. Yaffe K., Blackwell T., Kanaya A.M., Davidowitz N., Barrett-Connor E., and Krueger K. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63 (2004) 658-663
38. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 (2004) 2237-2242
39. Elias M.F., Elias P.K., Sullivan L.M., Wolf P.A., and D'Agostino R.B. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord 27 (2003) 260-268
40. Forette F., Seux M.L., Staessen J.A., Thijs L., Birkenhäger W.H., Babarskiene M.R., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998) 1347-1351
41. Tzourio C., Anderson C., Chapman N., Woodward N., Neal B., MacMahon S., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 (2003) 1069-1075
42. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
43. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
44. Starr J.M., Whalley L.J., and Deary I.J. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc 44 (1996) 411-415
45. Ishizaki J., Meguro K., Ohe K., Kimura E., Tsuchiya E., Ishii H., et al. Therapeutic psychosocial intervention for elderly subjects with very mild Alzheimer disease in a community: the tajiri project. Alzheimer Dis Assoc Disord 16 (2002) 261-269
46. Poon P., Hui E., Dai D., Kwok T., and Woo J. Cognitive intervention for community-dwelling older persons with memory problems: telemedicine versus face-to-face treatment. Int J Geriatr Psychiatry 20 (2005) 285-286